Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy.

Autor: Bullock K; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA., Richmond A; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.; Department of Veterans Affairs, Tennessee Valley Healthcare System, 432 PRB, 2220 Pierce Ave, Nashville, TN 37232, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Dec 15; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 15.
DOI: 10.3390/cancers13246293
Abstrakt: Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of cells derived from immature myeloid cells. These cells are often associated with poor responses to cancer therapy, including immunotherapy, in a variety of tumor types. The C-X-C chemokine receptor 2 (CXCR2) signaling axis plays a key role in the migration of immunosuppressive MDSCs into the tumor microenvironment (TME) and the pre-metastatic niche. MDSCs impede the efficacy of immunotherapy through a variety of mechanisms. Efforts to target MDSCs by blocking CXCR2 is an active area of research as a method for improving existing and novel immunotherapy strategies. As immunotherapies gain approval for a wider array of clinical indications, it will become even more important to understand the efficacy of CXCR2 inhibition in combating immunotherapy resistance at different stages of tumor progression.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje